| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2640 |
| Trial ID | NCT04826770 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran;mRNA-1273|Elasomeran|Spikevax |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Recruitment status | Active, Not Recruiting |
| Title | Blood Donations From Healthy Probands for the Study of the Adaptive Immune Response to COVID-19 Vaccination (AICOVI) |
| Year | 2021 |
| Country | Germany |
| Company sponsor | University Medicine Greifswald |
| Other ID(s) | BB 001/21f |
| Vector information | |||
|
|||
| Cohort1: BNT162b2_BNT162b2_BNT162b2 | |||||||
|
|||||||
| Cohort2: AZD 1222_BNT162b2_BNT162b2 | |||||||
|
|||||||
| Cohort3: AZD 1222_AZD 1222_BNT162b2 | |||||||
|
|||||||
| Cohort4: AZD 1222_mRNA-1273_BNT162b2 | |||||||
|
|||||||
| Cohort5: AZD 1222_BNT162b2_mRNA-1273 | |||||||
|
|||||||
| Cohort6: TRP study | |||||||
|
|||||||